On March 3rd, a new paper from the Memorial Sloan Kettering Cancer Center was published in Nature, entitled: "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection".
The Targeted Locus Amplification (TLA) technology was used to sequence and map the AAV integrations.
April 09, 2019
Cergentis releases two new application notes: improving QC in cell & gene therapy manufacturing with TLA
November 15, 2017
Meet us at the Cell Therapy Manufacturing & Gene Therapy Congress next month